Obesity and nonalcoholic fatty liver disease.
With the increasing prevalence of obesity and type 2 diabetes mellitus in the general population, nonalcoholic fatty liver disease (NAFLD) has become a common diagnosis in clinical practice. Insulin resistance and oxidative stress play an important role in NAFLD development and progression. NAFLD affects one in three adults and one in 10 children/adolescents in the United States. Mortality in patients with NAFLD is significantly higher than in the general population of same age and gender with liver-related complications. Lifestyle intervention may improve NAFLD, but medications that increase insulin sensitivity and the antioxidant defenses in the liver deserve evaluation in carefully controlled trials.
Angulo
Paul
P
Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. angulohernandez.paul@mayo.edu
D005234:Fatty Liver / Q000453:epidemiology* / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007333:Insulin Resistance; D008019:Life Style; D009765:Obesity / Q000150:complications*; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors